drugset / Trial / NCT01894568
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications. Participants will receive 26 weeks of treatment.
Timeline
- Start
- 2013-07
- Primary completion
- 2015-04
- Completion
- 2015-04
Outcome
Met primary endpoint
registry analysis (non-inferiority or equivalence test); Insulin Peglispro vs Insulin Glargine; p = 0.005; LS Mean Difference -0.24 (95% CI -0.41 to -0.07); Mixed Models Analysis NCT01894568 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Peglispro | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |
| Background | Pioglitazone | Small molecule | — | Oral |